Study Summaries

Pembrolizumab demonstrated clinical benefit in heavily pretreated advanced CCGC with a tolerable safety profile. Further evaluation in a randomized trial is warranted.

Pembrolizumab plus lenvatinib demonstrated promising anti-tumor activity with an objective response rate of 40% at 24 weeks in patients with recurrent gynaecological clear cell carcinoma.

Minimally invasive radical hysterectomy results in inferior DFS and OS compared to open surgery and is associated with higher recurrence and carcinomatosis. Open surgery should remain the standard of care.

Routine adjuvant extrafascial hysterectomy after radiation for bulky stage IB cervical carcinoma did not improve OS. Some benefit in local control and PFS was observed, particularly in patients with tumors 4–6 cm.

Avutometinib 3.2 mg BIW + defactinib 200 mg BID (3-weeks-on/1-week-off) produced clinically meaningful and durable responses with manageable toxicity in recurrent LGSOC

Camrelizumab plus famitinib significantly improves response rate and survival outcomes compared to camrelizumab alone or chemotherapy in pretreated R/M CC with a manageable safety profile.

Relacorilant plus nab-paclitaxel significantly prolonged PFS and showed a clinically meaningful interim OS improvement versus nab-paclitaxel alone, with manageable toxicity, positioning the combination as a potential new standard for platinum-resistant ovarian cancer.

Olaparib significantly improved PFS and ORR over nonplatinum chemotherapy, though no OS benefit was observed in the overall population. In patients with ≥3 prior therapies, chemotherapy had more favorable OS.

The addition of durvalumab with olaparib and cediranib did not improve PFS in platinum-resistant ovarian cancer patients with prior bevacizumab exposure.